Literature DB >> 1903912

In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci.

R J Fass1.   

Abstract

The in vitro activity of RP 59500, a semisynthetic pristinamycin, was compared with the activities of vancomycin, oxacillin, ampicillin, gentamicin, ciprofloxacin, and rifampin against five Staphylococcus species, five Streptococcus species, and four Enterococcus species. For staphylococci, MICs were 0.13 to 1 microgram/ml and the MICs for 90% of the strains tested (MIC90s) were 0.13 to 0.5 microgram/ml; there were no differences between oxacillin-susceptible and -resistant strains. For streptococci, MICs were 0.03 to 4 micrograms/ml and MIC90s were 0.25 to 2 micrograms/ml; viridans group streptococci were the least susceptible streptococci. For enterococci, MICs were 0.25 to 32 micrograms/ml and MIC90s were 2 to 4 micrograms/ml; Enterococcus faecalis was the least susceptible. Vancomycin was the only comparative drug with consistent activity against all species of gram-positive cocci. With RP 59500, raising the inoculum 100-fold, lowering the pH of cation-adjusted Mueller-Hinton broth to 5.5, or omitting cation supplementation had little effect on MICs, but 50% serum increased MICs 2 to 4 dilution steps. The differences between MBCs and MICs were greater for staphylococci and enterococci than for streptococci. Time-kill studies with 24 strains indicated that RP 59500 concentrations 2-, 4-, and 16-fold greater than the MICs usually killed bacteria of each species at similar rates; reductions in CFU per milliliter were less than those observed with oxacillin or vancomycin against staphylococci and less than those observed with ampicillin against enterococci. RP 59500 antagonized the bactericidal activities of oxacillin and gentamicin against Staphylococcus aureus ATCC 29213 and that of ampicillin against E. faecalis ATCC 29212. Against the latter, combination with gentamicin was indifferent. RP 59500 has a broad spectrum of in vitro activity against gram-positive cocci; combining it with other drugs is not advantageous.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1903912      PMCID: PMC245049          DOI: 10.1128/AAC.35.3.553

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

Review 1.  Antibiotics of the virginiamycin family, inhibitors which contain synergistic components.

Authors:  C Cocito
Journal:  Microbiol Rev       Date:  1979-06

2.  Phenotypic and genotypic heterogeneity of glycopeptide resistance determinants in gram-positive bacteria.

Authors:  S Dutka-Malen; R Leclercq; V Coutant; J Duval; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

3.  World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus.

Authors:  P A Maple; J M Hamilton-Miller; W Brumfitt
Journal:  Lancet       Date:  1989-03-11       Impact factor: 79.321

4.  Emergence of vancomycin resistance in coagulase-negative staphylococci.

Authors:  R S Schwalbe; J T Stapleton; P H Gilligan
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

5.  Comparative in vitro activities of pristinamycin, its components, and other antimicrobial agents against anaerobic bacteria.

Authors:  H Laforest; M Fourgeaud; H Richet; P H Lagrange
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

6.  In-vitro susceptibility of oral streptococci to pristinamycin.

Authors:  J P Maskell; J D Williams
Journal:  J Antimicrob Chemother       Date:  1987-05       Impact factor: 5.790

7.  In-vitro activity of pristinamycin and its components against gram-negative anaerobic bacilli and Gardnerella vaginalis.

Authors:  P Weber; S Dubois; Y Boussougant
Journal:  J Antimicrob Chemother       Date:  1989-06       Impact factor: 5.790

8.  Comparative in vitro activities of pristinamycin and other antimicrobial agents against genital pathogens.

Authors:  J C Lefevre; R Bauriaud
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

9.  Ampicillin-resistant enterococcal species in an acute-care hospital.

Authors:  S E Oster; V A Chirurgi; A A Goldberg; S Aiken; R E McCabe
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

10.  The in-vitro activity of pristinamycin against Haemophilus influenzae and Neisseria meningitidis.

Authors:  C Lafaix; E Bouvet; A Dublanchet; H Dabernat; C Carrere; J J Picq; J Etienne
Journal:  J Antimicrob Chemother       Date:  1985-07       Impact factor: 5.790

View more
  28 in total

1.  Bactericidal activity of quinupristin-dalfopristin against Staphylococcus aureus: clindamycin susceptibility as a surrogate indicator.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 2.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

3.  Post-antibiotic effect of the new streptogramin RP 59500.

Authors:  N X Chin; H C Neu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-07       Impact factor: 3.267

4.  In vitro antistaphylococcal activity and testing of RP 59500, a new streptogramin, by two methods.

Authors:  K E Aldridge; D D Schiro; L M Varner
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

5.  Provisional quality control parameters and interpretive criteria for testing susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to quinupristin/dalfopristin (RP59500). Antimicrobial Testing Quality Control Group.

Authors:  P Fuchs; A Barry; S Brown
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-03       Impact factor: 3.267

Review 6.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

Review 7.  Emerging resistance to antimicrobial agents in gram-positive bacteria. Enterococci, staphylococci and nonpneumococcal streptococci.

Authors:  M G Cormican; R N Jones
Journal:  Drugs       Date:  1996       Impact factor: 9.546

8.  In-vitro activity of synercid and related drugs against Streptococcus oralis isolated from septicaemia and endocarditis cases.

Authors:  A M Rafay
Journal:  J Sci Res Med Sci       Date:  2000-01

Review 9.  The evolving role of chemical synthesis in antibacterial drug discovery.

Authors:  Peter M Wright; Ian B Seiple; Andrew G Myers
Journal:  Angew Chem Int Ed Engl       Date:  2014-07-02       Impact factor: 15.336

10.  In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens.

Authors:  A L Barry; P C Fuchs
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.